Effect of operation combined with recombinant human erythropoietin on patients with severe intracerebral hemorrhage

Objective To observe the curative effect and safety of operation combined with recombinant human erythropoietin on patients with severe intracerebral hemorrhage. Methods Seventy-six surgery patients with severe intracerebral hemorrhage were divided into rHu-EPO group (40 cases) and control group (36 cases) by random digits table method. The rHu-EPO group was injected subcutaneously with rHu-EPO, and the control group was treated with placebo. Neurologic impairment (National Institute of Health Stroke Scale, NIHSS score) and activities of daily living (Barthel index) were evaluated 1 month and 3 months after treatment respectively. Moreover, blood pressure, hemoglobin, and adverse reaction were also observed. Results The scores of NIHSS and Barthel index in two groups before treatment had no significant differences (P >0.05). One month and 3 months after treatment, the scores of NIHSS and Barthel index in rHu-EPO group were significantly better: (12.27 ± 5.26) scores vs. (15.36 ± 4.34) scores and (8.17 ± 2.40) scores vs. (13.90 ± 2.54) scores, (54.36 ± 21.87) scores vs. (43.47 ± 20.29) scores and (69.71 ± 23.08) scores vs. (52.56 ± 21.32) scores, there were statistical differences(P 0.05). There were no apparente adverse reactions such as fever, erythra, itching and deep venous thrombosis in rHu-EPO group. Conclusions Operation combined with recombinant human erythropoietin has nerve protective effect, and might be an effective and safe therapy target in severe intracerebral hemorrhage. Key words: Erythropoietin; Cerebral hemorrhage; Surgery; Neurological function